The Home of the Life Sciences Industry

Explore Latest News


BMS Makes Potential $1.56 Billion Commitment to Agenus' Antibody Program

Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
Photo courtesy of Vedere Bio

Vedere Bio is Bypassing What’s Broken to Create Light in Vision Loss

The robust $77 million Series A was led by Octagon Capital and the leadership and research team behind the original Vedere Bio. 

Get personalized job alerts

Create a job alert and receive custom job recommendations straight to your inbox.


Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.

Post Jobs Now